It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective
To develop a computed tomography (CT) radiomics-based interpretable machine learning (ML) model to preoperatively predict human epidermal growth factor receptor 2 (HER2) status in bladder cancer (BCa) with multicenter validation.
Methods
In this retrospective study, 207 patients with pathologically confirmed BCa were enrolled and divided into the training set (n = 154) and test set (n = 53). Least absolute shrinkage and selection operator (LASSO) regression was used to identify the most discriminative features in the training set. Five radiomics-based ML models, namely logistic regression (LR), support vector machine (SVM), k-nearest neighbors (KNN), eXtreme Gradient Boosting (XGBoost) and random forest (RF), were developed. The predictive performance of established ML models was evaluated by the area under the receiver operating characteristic curve (AUC). The Shapley additive explanation (SHAP) was used to analyze the interpretability of ML models.
Results
A total of 1218 radiomics features were extracted from the nephrographic phase CT images, and 11 features were filtered for constructing ML models. In the test set, the AUCs of LR, SVM, KNN, XGBoost, and RF were 0.803, 0.709, 0.679, 0.794, and 0.815, with corresponding accuracies of 71.7%, 69.8%, 60.4%, 75.5%, and 75.5%, respectively. RF was identified as the optimal classifier. SHAP analysis showed that texture features (gray level size zone matrix and gray level co-occurrence matrix) were significant predictors of HER2 status.
Conclusions
The radiomics-based interpretable ML model provides a noninvasive tool to predict the HER2 status of BCa with satisfactory discriminatory performance.
Critical relevance statement
An interpretable radiomics-based machine learning model can preoperatively predict HER2 status in bladder cancer, potentially aiding in the clinical decision-making process.
Key Points
The CT radiomics model could identify HER2 status in bladder cancer.
The random forest model showed a more robust and accurate performance.
The model demonstrated favorable interpretability through SHAP method.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The First Affiliated Hospital of Chongqing Medical University, Department of Urology, Chongqing, China (GRID:grid.452206.7) (ISNI:0000 0004 1758 417X)
2 The First Affiliated Hospital of Fujian Medical University, Department of Urology, Urology Research Institute, Fuzhou, China (GRID:grid.412683.a) (ISNI:0000 0004 1758 0400); Fujian Medical University, Department of Urology, National Region Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307)
3 Chongqing University Fuling Hospital, Department of Urology, Chongqing, China (GRID:grid.190737.b) (ISNI:0000 0001 0154 0904)
4 Chongqing University Three Gorges Hospital, Department of Urology, Chongqing, China (GRID:grid.190737.b) (ISNI:0000 0001 0154 0904)
5 The First Affiliated Hospital of Chongqing Medical University, Department of Radiology, Chongqing, China (GRID:grid.452206.7) (ISNI:0000 0004 1758 417X)